Real-World Study Shows 83% of Early Alzheimer's Patients Stable or Improved on LEQEMBI
BIIB sits 58% above its 52-week low of $121.05.
Summary
New real-world data from the LEADER study show that 82.5% of early Alzheimer's patients on LEQEMBI remained stable or improved over an average of 17 months. The results, presented at AAIC 2026, were consistent across demographics and APOE genotypes. Safety findings aligned with the FDA label, with ARIA rates of 12.3% overall and no new serious events during maintenance dosing. This is the first large real-world dataset for LEQEMBI, reinforcing its clinical value outside trials. It follows the recent Diranersen Phase 2 results and the Apellis acquisition, adding to Biogen's Alzheimer's pipeline momentum. The data could strengthen payer discussions and physician adoption.
At the time of this announcement, BIIB was trading at $190.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.2B. The 52-week trading range was $121.05 to $219.72. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.